RAPT Therapeutics Management
Management criteria checks 2/4
RAPT Therapeutics' CEO is Brian Wong, appointed in Aug 2015, has a tenure of 9.25 years. total yearly compensation is $6.59M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 1.41% of the company’s shares, worth $1.10M. The average tenure of the management team and the board of directors is 4.8 years and 7.5 years respectively.
Key information
Brian Wong
Chief executive officer
US$6.6m
Total compensation
| CEO salary percentage | 9.2% |
| CEO tenure | 9.3yrs |
| CEO ownership | 1.4% |
| Management average tenure | 4.8yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus
Jul 24Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky
Jun 13
RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
May 20Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jan 25RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Oct 15RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study
Jun 14RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jun 08Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?
Mar 15We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth
Feb 15
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year
Jan 18RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction
Jan 08Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like
Dec 21The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares
Nov 23Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 19RAPT Therapeutics tumbles 25% despite promising FLX475 data in multiple cancers
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$120m |
| Mar 31 2024 | n/a | n/a | -US$118m |
| Dec 31 2023 | US$7m | US$605k | -US$117m |
| Sep 30 2023 | n/a | n/a | -US$109m |
| Jun 30 2023 | n/a | n/a | -US$99m |
| Mar 31 2023 | n/a | n/a | -US$93m |
| Dec 31 2022 | US$5m | US$580k | -US$84m |
| Sep 30 2022 | n/a | n/a | -US$79m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$73m |
| Dec 31 2021 | US$3m | US$540k | -US$69m |
| Sep 30 2021 | n/a | n/a | -US$64m |
| Jun 30 2021 | n/a | n/a | -US$60m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$4m | US$500k | -US$53m |
| Sep 30 2020 | n/a | n/a | -US$53m |
| Jun 30 2020 | n/a | n/a | -US$49m |
| Mar 31 2020 | n/a | n/a | -US$47m |
| Dec 31 2019 | US$2m | US$447k | -US$43m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$1m | US$425k | -US$36m |
Compensation vs Market: Brian's total compensation ($USD6.59M) is above average for companies of similar size in the US market ($USD655.65K).
Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.
CEO
Brian Wong (52 yo)
9.3yrs
Tenure
US$6,591,617
Compensation
Dr. Brian Russell Wong, M.D., Ph.D. serves as Venture Partner at The Column Group, LLC since joining the firm in 2022. He has been Chief Executive Officer and Director at RAPT Therapeutics, Inc. since Augu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.3yrs | US$6.59m | 1.41% $ 1.1m | |
| CFO, Principal Accounting Officer & Secretary | 4.9yrs | US$2.18m | 0.034% $ 26.2k | |
| Chief Medical Officer | 9.5yrs | US$1.90m | 0.045% $ 35.1k | |
| Vice President of Technology | no data | no data | no data | |
| Chief Scientific Officer | 5.4yrs | US$1.48m | 0.074% $ 57.6k | |
| General Counsel | 1.8yrs | no data | no data | |
| Chief Human Resources Officer | 2.5yrs | no data | no data | |
| Senior Vice President of Quantitative & Computational Biology | 4.7yrs | no data | no data | |
| Senior Vice President of Drug Discovery & Preclinical Development | 5.8yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 2.2yrs | no data | no data | |
| Senior Vice President of Technical Operations | less than a year | no data | no data |
4.8yrs
Average Tenure
57.5yo
Average Age
Experienced Management: RAPT's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.3yrs | US$6.59m | 1.41% $ 1.1m | |
| Independent Chairman of the Board | 9.5yrs | US$300.28k | 0.27% $ 211.2k | |
| Independent Director | 4.9yrs | US$277.78k | 0% $ 0 | |
| Member of Scientific Advisory Board | 7.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.5yrs | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 7.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.3yrs | no data | no data | |
| Independent Director | 6.8yrs | US$267.78k | 0% $ 0 | |
| Independent Director | 7.9yrs | US$260.78k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
7.5yrs
Average Tenure
65yo
Average Age
Experienced Board: RAPT's board of directors are considered experienced (7.5 years average tenure).